NewsSource: EClinCloud

Livestream Preview | How to Apply eCOA to Achieve Patient-Centric Clinical Research?

4 min readEClinCloud Editorial Team
Article illustration

Source: EClinCloud. Author: EClinCloud.

In 2021, the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) issued a series of guidance documents explicitly encouraging the use of eCOA/ePRO tools in drug clinical research. This indicates that eCOA is gradually transitioning from an "early awareness phase" to a "mature application phase." At this stage, clinical trial leaders at pharmaceutical companies and CROs commonly face the following questions:

What is the value of eCOA compared with Paper COA?
Can eCOA data be modified as source data?
What kind of eCOA system meets regulatory requirements?

To address these questions, on October 19, 2022, 16:00–17:30, EClinCloud will partner with Dongmai Yanxuan (动脉严选) to co-host a live online webinar titled "How to Apply eCOA to Achieve Patient-Centric Clinical Research?" During the session, Dr. Qin Long, CEO of EClinCloud, will share a forward-looking perspective and provide pharmaceutical companies and CROs with a detailed introduction to all aspects of eCOA.

In addition, this session has invited Dr. Shen Yifeng, Chief Physician at the Shanghai Mental Health Center, and Dr. Guo Tong, Vice President of Business Development for Greater China at IQVIA, to join a roundtable discussion on [The Significance and Value of eCOA for Patient-Centric Clinical Trials] to help pharmaceutical companies and CROs identify the right methodology based on case experience.

For the first 20 audience members who participate in the live interactive consultation, EClinCloud is also offering a 3-month trial of its SaaS system (choice of one from EDC, RTSM, CTMS, eTMF, eCOA, etc.). During the livestream, attendees will also have the opportunity to receive a cash red packet! Scan the QR code on the poster below to register for the livestream:

Article illustration


Key Topics of This Webinar




1. What is eCOA?
2. How do global regulatory authorities view the use of eCOA?
3. The value of eCOA compared with Paper COA
4. Can eCOA data be modified as source data?
5. What kind of eCOA system meets regulatory requirements?


Target Audience for This Webinar




Founders and partners of companies with innovative clinical research projects
[Recommendation Level: ★★★★★]

Heads of clinical trial-related departments at companies with innovative clinical research projects
[Recommendation Level: ★★★★]

eCOA system administrators in clinical trial-related departments at companies with innovative clinical research projects
[Recommendation Level: ★★★]

If you belong to any of the groups above, be sure not to miss this informative live webinar.


Speaker Introductions




Dr. Qin Long | CEO, EClinCloud
Article illustration
Article illustration
 
He holds a Ph.D. in Management from Beihang University and conducted postdoctoral research in medical statistics at Sun Yat-sen University. With over 16 years of experience in technology applications in the clinical research industry, he is an innovative and inspiring leader and a pioneer in promoting and implementing technology solutions such as eCOA, EDC, and CTMS in China's clinical trial research field. He previously served as Head of Asia-Pacific for an international technology company, leading rapid business growth across the region, and is an entrepreneur driven by academia and science who is passionately committed to shaping future clinical trial models.

Dr. Shen Yifeng | Chief Physician, Director of the Clinical Trial Institution Office, and Ethics Committee Member, Shanghai Mental Health Center

Article illustration
 
Chief Physician, Director of the Clinical Trial Institution Office, and Ethics Committee Member at the Shanghai Mental Health Center. From 2008 to 2020, he served as Deputy Leader of the Psychotropic Drug GCP Platform under the National Science and Technology Major Project for "Major New Drug Innovation and Development," and is also a Core Member of the China QA Forum.

Dr. Guo Tong | Vice President of Business Development, Greater China, IQVIA

Article illustration
 
Holds master's and doctoral degrees in biostatistics from McGill University in Canada. Brings over 20 years of senior industry experience in biostatistics, clinical operations, and corporate management across domestic Chinese and global pharmaceutical companies, and has led the statistical design and analysis of multiple global multicenter clinical trials, with extensive research experience in clinical trial design and analysis, real-world research, healthcare big data, and artificial intelligence applications.

About EClinCloud


EClinCloud is a healthcare and life-technology company based in China and serving the world. Guided by its mission of "bringing effective treatments to patients through technological innovation" and driven by science and medicine, it combines digital technology with life data to build an end-to-end digital clinical trial cloud platform and provide technical solutions for clinical endpoint assessment, helping domestic and international pharmaceutical companies and research institutions improve R&D efficiency, accelerate the time to market for drugs/devices, and benefit countless patients.




Article illustration

Read the original WeChat post

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.